title: Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy.
abstract: BACKGROUND
  Gaucher disease is the first lysosomal disease to benefit from enzyme replacement therapy, thus serving as model for numerous other lysosomal diseases. Alglucerase was the first glucocerebrosidase purified from placental extracts, and this was then replaced by imiglucerase - a Chinese hamster ovary cell-derived glucocerebrosidase.
  
  
  OBJECTIVE
  The aim was to review the evidence underlying the use of imiglucerase in Gaucher disease type 1.
  
  
  METHODS
  Data from clinical trials and Gaucher Registries were analyzed.
  
  
  CONCLUSIONS
  Imiglucerase has been prescribed and found to have an excellent efficacy and safety profile. We report herein the evidence-based data published for 26 years justifying the use of imiglucerase.
authors: Department of Internal Medicine and Rehabilitation, Geneva University Hospital, Thonex, Switzerland.
authors: Christine
authors: C
authors: Serratrice
authors: Department of General Internal Medicine, Geneva University Hospital, Geneva, Switzerland.
authors: Sebastian
authors: S
authors: Carballo
authors: Department of General Internal Medicine, Geneva University Hospital, Geneva, Switzerland.
authors: Jacques
authors: J
authors: Serratrice
authors: Department of General Internal Medicine, Geneva University Hospital, Geneva, Switzerland.
authors: Jérome
authors: J
authors: Stirnemann
keywords: Gaucher disease; imiglucerase; lysosomal disease; safety; therapeutic goals; treatment